Next Article in Journal
Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis
Next Article in Special Issue
TIM-3 Expression Is Downregulated on Human NK Cells in Response to Cancer Targets in Synergy with Activation
Previous Article in Journal
Molecular Biology of Osteosarcoma
Previous Article in Special Issue
Genetic and Molecular Basis of Heterogeneous NK Cell Responses against Acute Leukemia
Review
Peer-Review Record

Natural Born Killers: NK Cells in Cancer Therapy

Cancers 2020, 12(8), 2131; https://doi.org/10.3390/cancers12082131
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Cancers 2020, 12(8), 2131; https://doi.org/10.3390/cancers12082131
Received: 6 July 2020 / Revised: 21 July 2020 / Accepted: 27 July 2020 / Published: 31 July 2020
(This article belongs to the Special Issue The Role of NK and T Cells in Cancer)

Round 1

Reviewer 1 Report

Optional: An updated on the Wels study with Her-2 new NK-92 cells is mentioned in: https://www.frontiersin.org/articles/10.3389/fimmu.2019.02683/full

Also suggest to quote an ASH abstract from 2018 describing a t-haNK for CD19 engineered to express the CCR7 homing receptor (abstract #116890)

Author Response

July 20, 2020

 

Re: cancers-875047

 

Natural Born Killers: NK Cells in Cancer Therapy

 

Specific Points:

 

NOTE: Changes in BLUE

 

REVIEWER 1:

  1. An updated on the Wels study with Her-2 new NK-92 cells is mentioned in: https://www.frontiersin.org/articles/10.3389/fimmu.2019.02683/full

 

Response:

            We thank the reviewer for this suggestion. The article mentioned is a review (CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy). We have now referenced the trials discussed in the review (manuscript references 99-102).

 

  1. Also suggest to quote an ASH abstract from 2018 describing a t-haNK for CD19 engineered to express the CCR7 homing receptor (abstract #116890) all in-vitro
     

Response:

            We understand. The noytes ASH abstract describes the in-vitro utilization of  a t-haNK for CD19 engineered to express the CCR7 homing receptor. To focus our review, we limited our comments to clinical data at the expense of in-vitro only data. If the reviewer insists, we can add it.

 

Reviewer 2 Report

Well written review article on NK cells in cancer therapy that includes several pertinent recent studies. Concise and very easy to read. Figures are well-done, clear and self-explanatory.

Some minor comments that should be addressed:

  1. please include trade names of the drugs in lines 39 and 40.
  2. include the word "cell" after NK in lines 83, 86 and 88.
  3. Should include a brief discussion on the cytotoxic molecules referred to in line 128.
  4. the authors refer to several CAR-NK therapy in lines 324-329. Are these using NK-92 cell line or primary human NK cels. A sentence should be added to clarify this.
  5. what does t-ha-NK refer to in line 356 ? please clarify.
  6. spell out TME in line 332.
  7. please include appropriate reference for the statement in lines 465-467.

Author Response

July 20, 2020

 

Re: cancers-875047

 

Natural Born Killers: NK Cells in Cancer Therapy

 

Specific Points:

 

NOTE: Changes in BLUE

 

 

REVIEWER 2: 

 

  1. Please include trade names of the drugs in lines 39 and 40.

 

Response:

            We appreciate this comment. However, as United States Federal Employees, we are forbidden form listing trade names, as this may imply an endorsement of a particulat drug by the government. We are strongly encouraged to use the generic names for drugs.

 

  1. include the word "cell" after NK in lines 83, 86 and 88.

 

Response:

            As suggested, this has now been added.

 

  1. Should include a brief discussion on the cytotoxic molecules referred to in line 128.

 

Response:

            Thank you for this comment. As suggested, this has now been added.

 

  1. the authors refer to several CAR-NK therapy in lines 324-329. Are these using NK-92 cell line or primary human NK cells. A sentence should be added to clarify this.

 

Response:

            As recommended, we have now clarified this in Table 1.

 

  1. what does t-ha-NK refer to in line 356 ? please clarify.

 

Response:

            Thanks. This has now been clarified.

 

  1. spell out TME in line 332.

 

Response:

            Thank you. As suggested, this has now been clarified.  

 

  1. please include appropriate reference for the statement in lines 465-467.

 

Response:

This has now been completed.

Back to TopTop